Skip To Main Content
Yingge Lv on Muck Rack

Yingge Lv

As seen in: Wiley Online Library, BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingge

Contact Yingge, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dual Aptamers-Based SETDB1 PROTACs as Effective Anti-Tumor Strategies for Breast Cancer (Adv. Sci. 18/2026)

|
By Yanxuan Guo, Yingge Lv, Shuyu Huang
| Wiley Online Library Verified
Advanced Hub Main Navigation Menu Guo, Y., Lv, Y., Huang, S., Liu, C., Ouyang, Y., Lan, B. and Xuan, C. (2026), Dual Aptamers-Based SETDB1 PROTACs as Effective Anti-Tumor Strategies for Breast Cancer (Adv. Sci. 18/2026). Adv. Sci., 13: e74638. https://doi.org/10.1002/advs.74638 Scite metrics Explore this article's citation statements on scite.ai powered by Generating QR code Select Format Something went wrong while generating your QR code. Please try again in a moment.
Open in Who Shared View Duplicates (28) Issue with article?

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

|
By Yingge Lv, Shuyu Huang, Chang Liu, Yanxuan Guo
| Wiley Online Library Verified
1 Introduction Targeted protein degradation (TPD) technology has emerged as a powerful strategy for targeting traditionally “undruggable” proteins, significantly expanding the range of druggable targets. This innovative approach utilizes a recognition moiety that selectively binds to the target protein, facilitating its degradation through the protein hydrolysis pathway [1].
Open in Who Shared Issue with article?

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation - BMC Cancer

|
By Lu Wang Verified, Weihong Zhang, Yuan Meng, Yang Wang, Meng Shen, Li Zhou Verified, Runmei Li, Yingge Lv, Shengguang Wang, Xiubao Ren, Liang Liu, Yanjuan Xiong
| BMC Cancer Verified
The study was conducted following the principles of the Helsinki Declaration, and written informed consent was obtained from all patients prior to enrollment.
Open in Who Shared Issue with article?
See all 4 articles